

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wybe Martin Kast et al.  
Serial No. : 08/170,344  
Filed : March 30, 1994  
For : PEPTIDES OF HUMAN PAPILLOMA VIRUS FOR USE IN  
HUMAN T CELL RESPONSE INDUCING COMPOSITIONS

30 Rockefeller Plaza  
New York, New York 10112  
July 14, 1994

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821 (f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same information which is submitted in the subject application under the section entitled "Sequence Listing".

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

Applicants: Wybe Martin Kast et al.  
U.S. Serial No.: 08/170,344  
U.S. Filing Date: March 30, 1994  
Page 2

United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Richard S. Milner", is written over the printed name "Thomas F. Moran".

Thomas F. Moran  
Reg. No. 16,579  
Richard S. Milner  
Reg. No. 33,970  
Cooper & Dunham  
30 Rockefeller Plaza  
New York, New York 10112  
(212) 977-9550

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and, or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7.

Other: \_\_\_\_\_

**Applicant must provide:**

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

BEST AVAILABLE COPY

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
 For CRF submission help, call (703) 308-4212  
 For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.